MEDIUM confidence: 100% data completeness, but the composite (58) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $443M— | $660M+48.9% | $829M+25.6% | $1.0B+22.4% | $1.4B+37.6% |
| EPS (dil.) | $2.74— | $1.44-47.4% | $2.10+45.8% | $3.43+63.3% | $2.56-25.4% |
| Free Cash Flow | $298M— | $235M-21.0% | $373M+58.6% | $468M+25.5% | $645M+37.6% |
| Gross Margin | 81.6% | 78.9%-2.7pp | 76.8%-2.1pp | 84.3%+7.5pp | 78.1%-6.2pp |
| Operating Margin | 62.2% | 40.5%-21.7pp | 40.7%+0.2pp | 54.3%+13.6pp | 58.4%+4.1pp |
| Net Margin | 90.8% | 30.6%-60.2pp | 34.0%+3.3pp | 43.7%+9.8pp | 22.7%-21.0pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $103 (last qtr, 5 analysts) → $106 (last mo, 4) (+3.2%).
Buy-rated share 60% → 67% over ~3 months (+7pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $1.79 | $2.28 | +27.4% |
| May 2026 | $1.55 | $1.60 | +3.2% |
| Feb 2026 | $2.15 | $-0.24 | -111.2% |
| Nov 2025 | $1.63 | $1.72 | +5.5% |
| Aug 2025 | $1.23 | $1.54 | +25.2% |
| May 2025 | $0.95 | $1.11 | +16.8% |
| Feb 2025 | $1.17 | $1.26 | +7.7% |
| Oct 2024 | $0.98 | $1.27 | +29.6% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 0.2%/yr (revenue basis).
Base free cash flow $495M (avg FY2023–FY2025; latest year $645M) · equity value $11.9B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$16.7M over 180 days (0 open-market buys, 45 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 58 for Halozyme Therapeutics indicates a moderately positive outlook, driven by strong scores in profitability and momentum, with the latter exhibiting a 12-month return of 56.7% and an ROE near 180%. The stock's growth score is also relatively high, despite a decline in EPS, due to 37.6% revenue growth. However, the value score is dragged down by a high P/E of 28.6 and a P/B of 82.2, indicating the stock trades at a premium. The short-term score is slightly higher than the long-term score, at 61 versus 55.